Associations between the EQ-5D-5L and exacerbations of chronic obstructive pulmonary disease in the ETHOS trial
-
Published:2024-01-11
Issue:
Volume:
Page:
-
ISSN:0962-9343
-
Container-title:Quality of Life Research
-
language:en
-
Short-container-title:Qual Life Res
Author:
Jackson Dan,Jenkins Martin,de Nigris Enrico,Purkayastha Debasree,Patel Mehul,Ouwens Mario
Abstract
Abstract
Purpose
Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with deteriorating health and health-related quality of life (HRQoL) among people with COPD during and after events. HRQoL data are key to evaluating treatment cost-effectiveness and informing reimbursement decisions in COPD. EuroQoL 5-dimension 5-level (EQ-5D-5L) utility scores, based on various HRQoL measures, are used in economic evaluations of pharmacotherapy. These analyses estimated associations between EQ-5D-5L utility scores and exacerbations (new and previous) in patients with moderate-to-very severe COPD.
Methods
Longitudinal mixed models for repeated measures (MMRM), adjusted for time and treatment, were conducted using data from the ETHOS study (NCT02465567); models regressed EQ-5D-5L on current and past exacerbations that occurred during the study, adjusting for other patient reported outcomes and clinical factors.
Results
Based on the simplest covariate adjusted model (adjusted for current exacerbations and number of previous exacerbations during the study), a current moderate exacerbation was associated with an EQ-5D-5L disutility of 0.055 (95% confidence interval: 0.048, 0.062) with an additional disutility of 0.035 (0.014, 0.055) if the exacerbation was severe. After resolving, each prior exacerbation was associated with a disutility that persisted for the remainder of the study (moderate exacerbation, 0.014 [0.011, 0.016]; further disutility for severe exacerbation, 0.011 [0.003, 0.018]).
Conclusion
An EQ-5D-5L disutility of 0.090 was associated with a current severe exacerbation in ETHOS. Our findings suggest incorporating the effects of current, recently resolved, and cumulative exacerbations into economic models when estimating benefits and costs of COPD pharmacotherapy, as exacerbations have both acute and persistent effects.
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference28 articles.
1. Global Initiative for Chronic Obstructive Lung Disease. (2022). 2022 GOLD Report. Global strategy for the diagnosis, management and prevention of COPD. Retrieved February 2, 2022, from https://goldcopd.org/2022-gold-reports-2/ 2. World Health Organization. (2020, December 9th, 2020). The top 10 causes of death. Retrieved December 8, 2021, from https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death 3. Ko, F. W., Chan, K. P., Hui, D. S., Goddard, J. R., Shaw, J. G., Reid, D. W., & Yang, I. A. (2016). Acute exacerbation of COPD. Respirology, 21(7), 1152–1165. https://doi.org/10.1111/resp.12780 4. Hurst, J. R., Skolnik, N., Hansen, G. J., Anzueto, A., Donaldson, G. C., Dransfield, M. T., & Varghese, P. (2020). Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. European Journal of Internal Medicine, 73, 1–6. https://doi.org/10.1016/j.ejim.2019.12.014 5. Miravitlles, M., Peña-Longobardo, L. M., Oliva-Moreno, J., & Hidalgo-Vega, Á. (2015). Caregivers’ burden in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease, 10, 347–356. https://doi.org/10.2147/COPD.S76091
|
|